| Print
Novavax (NVAX)
Common SharesOpen
$6.61
Previous close
$6.705
Trade high
$6.71
Volume
5,079,456
Year high
$23.8599
Year low
$4.25
Dividend yield
–
Market capitalisation
$1.03 bn
P/E ratio
–
ISIN
US6700024010
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Share price
Company profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly ownedSwedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Thecompany manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.